ISSUE 1539
| The full article is available to subscribers | Subscriber Login |
The FDA has approved semaglutide (Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the sixth GLP-1 receptor agonist to be approved in the US.
GLP-1 RECEPTOR AGONISTS — GLP-1 receptor agonists lower glucose levels by potentiating glucose-dependent secretion of insulin, suppressing postprandial glucagon secretion, slowing gastric emptying, and promoting satiety. They lower glycated hemoglobin (A1C) by about 1-1.5%, have been associated with average weight loss of 1.5-2.8 kg, and rarely cause hypoglycemia.1
Cardiovascular Effects – In patients with type 2 diabetes and high cardiovascular risk, addition of liraglutide (Victoza) to standard therapy has been shown to reduce the rates of major
... more- Drugs for type 2 diabetes. Med Lett Drugs Ther 2017; 59:9.
- SP Marso et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311.
- MA Pfeffer et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247.
- RR Holman et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377:1228.
- AJ Ahmann et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 2017 Dec 15 (epub).
- RE Pratley et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomized, openlabel, phase 3b trial. Lancet Diabetes Endocrinol 2018 Jan 31 (epub).
- SP Marso et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834.
- MA Bethel et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2017 Dec 5 (epub).
- T Vilsbøll et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2017 Nov 27 (epub).
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1539b
Electronic, downloadable article - $45
